Drugs / ACORAFLOXACIN
last change Oct 2011 re-read 2 minutes ago

ACORAFLOXACIN

Small molecule

Developed for
bacterial pneumonia
Investigated by
Furiex Pharmaceuticals, Inc

Trials 2 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01198626 Oct 2010 → Oct 2011 bacterial pneumonia Furiex Pharmaceuticals, Inc Terminated No outcome recorded
Phase 2 NCT01128530 Jun → Dec 2010 Furiex Pharmaceuticals, Inc Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ACORAFLOXACIN ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as ACORAFLOXACIN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as Acorafloxacine ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as Acorafloxacino ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as JNJ-32729463 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01198626
1

NCT01128530

Known as JNJ-32729463-AAA ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as JNJ-32729463-AAC ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as JNJ-Q2 ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Known as Jnj-q2 hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL1257096
Modality Small molecule CHEMBL1257096
Route Oral “250 mg BID oral dose of JNJ-32729463” NCT01128530